First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in cardiology 2017-01, Vol.2017 (2017), p.1-3
Main Authors: Salciccioli, Louis, Meade, Matthew, Goulbourne, Clive, Cook, Joselle, Song, Steven, Lazar, Jason M.
Format: Article
Language:English
Subjects:
Anticoagulants
Blood
Cardiac arrhythmia
Case Report
Chemotherapy
Clinical trials
Drug dosages
Glycoproteins
Hemorrhage
Laboratories
Neutropenia
Patients
Pneumonia
Tomography
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3
cites cdi_FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3
container_end_page 3
container_issue 2017
container_start_page 1
container_title Case reports in cardiology
container_volume 2017
creator Salciccioli, Louis
Meade, Matthew
Goulbourne, Clive
Cook, Joselle
Song, Steven
Lazar, Jason M.
description Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.
doi_str_mv 10.1155/2017/6458636
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5b471382e6b84ab0a2ff9cb73e73765e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5b471382e6b84ab0a2ff9cb73e73765e</doaj_id><sourcerecordid>4323017675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3</originalsourceid><addsrcrecordid>eNqFkt1rFDEUxQdRbKl981kGfNS1ufmcvAhltXahKBT7HG5mbrYpu5M1M9NS_3qzzlLpk08JOT9O7uHcqnoL7BOAUmecgTnTUjVa6BfVMWeWLbQE_vLpzuRRdToM0TMpjeCai9fVEW-0VQzscRUuYh7G-pp2KY_U1UscqE6hvqRt2lGOLeYuTtsCbHCvj6n-gj6ucczY1zcFvqZ7ykOR_GP9nR7q836MXRqpXnWYpzb-nrbo31SvAm4GOj2cJ9XNxdefy8vF1Y9vq-X51aIt44wLG7RsrLKWIweFZUxugtACiKS2jQmBsU4BcMWkZtC1gUllwCipQyDlxUm1mn27hHdul-MW86NLGN3fh5TXDvMY2w055aUB0XDSvpHoGfIQbOuNICOMVlS8Ps9eu8lvqWupL5k3z0yfK328det075RsGgFQDN4fDHL6NdEwurs05b7kd2ChxGrK5IX6OFNtTsOQKTz9AMztS3b7kt2h5IJ_mPHb2Hf4EP9Hv5tpKgwF_EeDLGtixB-J1624</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1913638175</pqid></control><display><type>article</type><title>First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab</title><source>PubMed (Medline)</source><source>Wiley-Blackwell Open Access Titles (Open Access)</source><source>Publicly Available Content (ProQuest)</source><creator>Salciccioli, Louis ; Meade, Matthew ; Goulbourne, Clive ; Cook, Joselle ; Song, Steven ; Lazar, Jason M.</creator><contributor>Baumhäkel, Magnus</contributor><creatorcontrib>Salciccioli, Louis ; Meade, Matthew ; Goulbourne, Clive ; Cook, Joselle ; Song, Steven ; Lazar, Jason M. ; Baumhäkel, Magnus</creatorcontrib><description>Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.</description><identifier>ISSN: 2090-6404</identifier><identifier>EISSN: 2090-6412</identifier><identifier>DOI: 10.1155/2017/6458636</identifier><identifier>PMID: 28695019</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Anticoagulants ; Blood ; Cardiac arrhythmia ; Case Report ; Chemotherapy ; Clinical trials ; Drug dosages ; Glycoproteins ; Hemorrhage ; Laboratories ; Neutropenia ; Patients ; Pneumonia ; Tomography ; Ultrasonic imaging</subject><ispartof>Case reports in cardiology, 2017-01, Vol.2017 (2017), p.1-3</ispartof><rights>Copyright © 2017 Steven Song et al.</rights><rights>Copyright © 2017 Steven Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Steven Song et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3</citedby><cites>FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3</cites><orcidid>0000-0002-8735-8050 ; 0000-0002-6216-0259</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1913638175/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1913638175?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25732,27903,27904,36991,44569,53770,53772,74873</link.rule.ids></links><search><contributor>Baumhäkel, Magnus</contributor><creatorcontrib>Salciccioli, Louis</creatorcontrib><creatorcontrib>Meade, Matthew</creatorcontrib><creatorcontrib>Goulbourne, Clive</creatorcontrib><creatorcontrib>Cook, Joselle</creatorcontrib><creatorcontrib>Song, Steven</creatorcontrib><creatorcontrib>Lazar, Jason M.</creatorcontrib><title>First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab</title><title>Case reports in cardiology</title><description>Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.</description><subject>Anticoagulants</subject><subject>Blood</subject><subject>Cardiac arrhythmia</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Glycoproteins</subject><subject>Hemorrhage</subject><subject>Laboratories</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Tomography</subject><subject>Ultrasonic imaging</subject><issn>2090-6404</issn><issn>2090-6412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFkt1rFDEUxQdRbKl981kGfNS1ufmcvAhltXahKBT7HG5mbrYpu5M1M9NS_3qzzlLpk08JOT9O7uHcqnoL7BOAUmecgTnTUjVa6BfVMWeWLbQE_vLpzuRRdToM0TMpjeCai9fVEW-0VQzscRUuYh7G-pp2KY_U1UscqE6hvqRt2lGOLeYuTtsCbHCvj6n-gj6ucczY1zcFvqZ7ykOR_GP9nR7q836MXRqpXnWYpzb-nrbo31SvAm4GOj2cJ9XNxdefy8vF1Y9vq-X51aIt44wLG7RsrLKWIweFZUxugtACiKS2jQmBsU4BcMWkZtC1gUllwCipQyDlxUm1mn27hHdul-MW86NLGN3fh5TXDvMY2w055aUB0XDSvpHoGfIQbOuNICOMVlS8Ps9eu8lvqWupL5k3z0yfK328det075RsGgFQDN4fDHL6NdEwurs05b7kd2ChxGrK5IX6OFNtTsOQKTz9AMztS3b7kt2h5IJ_mPHb2Hf4EP9Hv5tpKgwF_EeDLGtixB-J1624</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Salciccioli, Louis</creator><creator>Meade, Matthew</creator><creator>Goulbourne, Clive</creator><creator>Cook, Joselle</creator><creator>Song, Steven</creator><creator>Lazar, Jason M.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8735-8050</orcidid><orcidid>https://orcid.org/0000-0002-6216-0259</orcidid></search><sort><creationdate>20170101</creationdate><title>First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab</title><author>Salciccioli, Louis ; Meade, Matthew ; Goulbourne, Clive ; Cook, Joselle ; Song, Steven ; Lazar, Jason M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anticoagulants</topic><topic>Blood</topic><topic>Cardiac arrhythmia</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Glycoproteins</topic><topic>Hemorrhage</topic><topic>Laboratories</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Tomography</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salciccioli, Louis</creatorcontrib><creatorcontrib>Meade, Matthew</creatorcontrib><creatorcontrib>Goulbourne, Clive</creatorcontrib><creatorcontrib>Cook, Joselle</creatorcontrib><creatorcontrib>Song, Steven</creatorcontrib><creatorcontrib>Lazar, Jason M.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Case reports in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salciccioli, Louis</au><au>Meade, Matthew</au><au>Goulbourne, Clive</au><au>Cook, Joselle</au><au>Song, Steven</au><au>Lazar, Jason M.</au><au>Baumhäkel, Magnus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab</atitle><jtitle>Case reports in cardiology</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>3</epage><pages>1-3</pages><issn>2090-6404</issn><eissn>2090-6412</eissn><abstract>Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28695019</pmid><doi>10.1155/2017/6458636</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-8735-8050</orcidid><orcidid>https://orcid.org/0000-0002-6216-0259</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-6404
ispartof Case reports in cardiology, 2017-01, Vol.2017 (2017), p.1-3
issn 2090-6404
2090-6412
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5b471382e6b84ab0a2ff9cb73e73765e
source PubMed (Medline); Wiley-Blackwell Open Access Titles (Open Access); Publicly Available Content (ProQuest)
subjects Anticoagulants
Blood
Cardiac arrhythmia
Case Report
Chemotherapy
Clinical trials
Drug dosages
Glycoproteins
Hemorrhage
Laboratories
Neutropenia
Patients
Pneumonia
Tomography
Ultrasonic imaging
title First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A15%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20Reported%20Case%20of%20Hemopericardium%20Related%20to%20Dabigatran%20Use%20Reversed%20by%20New%20Antidote%20Idarucizumab&rft.jtitle=Case%20reports%20in%20cardiology&rft.au=Salciccioli,%20Louis&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=3&rft.pages=1-3&rft.issn=2090-6404&rft.eissn=2090-6412&rft_id=info:doi/10.1155/2017/6458636&rft_dat=%3Cproquest_doaj_%3E4323017675%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c501t-9f64895992a215a28627f3631ee46987ff00d5112504601dcf045717546ffe5b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1913638175&rft_id=info:pmid/28695019&rfr_iscdi=true